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Abstract
Intrinsic radiosensitivity is an important factor underlying radiotherapy response, but there is no method for its routine
assessment in human tumours. Gene signatures are currently being derived and some were previously generated by
expression profiling the NCI-60 cell line panel. It was hypothesised that focusing on more homogeneous tumour types
would be a better approach. Two cell line cohorts were used derived from cervix [n = 16] and head and neck [n = 11]
cancers. Radiosensitivity was measured as surviving fraction following irradiation with 2 Gy (SF2) by clonogenic assay.
Differential gene expression between radiosensitive and radioresistant cell lines (SF2,/. median) was investigated using
Affymetrix GeneChip Exon 1.0ST (cervix) or U133A Plus2 (head and neck) arrays. There were differences within cell line
cohorts relating to tissue of origin reflected by expression of the stratified epithelial marker p63. Of 138 genes identified as
being associated with SF2, only 2 (1.4%) were congruent between the cervix and head and neck carcinoma cell lines (MGST1
and TFPI), and these did not partition the published NCI-60 cell lines based on SF2. There was variable success in applying
three published radiosensitivity signatures to our cohorts. One gene signature, originally trained on the NCI-60 cell lines, did
partially separate sensitive and resistant cell lines in all three cell line datasets. The findings do not confirm our hypothesis
but suggest that a common transcriptional signature can reflect the radiosensitivity of tumours of heterogeneous origins.
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Introduction
Intrinsic radiosensitivity is an important factor underlying
radiotherapy response [1]. Radiosensitivity can be measured as
the fraction of cells surviving a single 2 Gy dose of radiation (SF2)
with high values indicating radioresistance. While other methods
are available to measure cellular radiosensitivity in cell lines, SF2 is
considered to be the gold standard and is supported by strong
clinical evidence. In vitro measurements of SF2 correlate with in vivo
radioresponse in mouse models [2]. Measurement of SF2 in
primary human tumours was an independent prognostic factor in
patients with carcinoma of the cervix [3] and head and neck [4]
following potentially curative radiotherapy. Despite the evidence
for its importance, no method is available for its routine assessment
in patients, due to the impracticalities of measuring tumour
radiosensitivity. The ability to measure a tumour’s radiosensitivity
would be a major advance and allow individualised treatment to
reduce dose and/or omit chemotherapy in patients with sensitive
tumours or conversely to intensify treatment against resistant
tumours. Treatment individualisation should increase survival and
reduce morbidity. Estimates suggest a biologically individualised
approach to treatment based on radiosensitivity testing could
increase survival rates by .10% [5].
Consequently there is interest in deriving a gene signature that
reflects radiosensitivity. Several methods have been explored:
identifying genes induced following irradiation in cell lines [6];
identifying differential expression between induced radioresistant
and parental radiosensitive cancer cell lines [7] and profiling the
in vitro response of cervix tumours to irradiation [8]. Most
published studies were small and have not been independently
validated. The most comprehensive studies used the NCI-60 panel
of cell lines [9]. One study identified 22 genes that together
discriminated between low and high SF2 values in 63 cell lines,
based on a threshold of 0.2 (i.e. cell lines with less than 20% colony
survival following 2 Gy defined as radiosensitive) [10]. Another
series of studies developed a predictive classifier of radiosensitivity
based on SF2 associated gene expression profiles in the NCI-60
lines [11,12,13,14]. The endpoint of these studies was a regression
model of 10-hub genes, which had prognostic significance when
applied to three clinical datasets (rectal, oesophageal and head &
neck cancers) [13] and was also predictive of benefit from
radiotherapy in breast cancer [15]. Additionally a meta-analysis of
published data from four microarray platforms for NCI-60 cells
identified a 31 gene radiosensitivity signature [16].
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The NCI-60 panel is the most extensively characterised set of
cancer cell lines and a public resource that is frequently used as a
screening tool for drug discovery [9]. The panel contains cell lines
from multiple tissues of origin but few radiobiologically relevant
tumour types such as cervix (n = 0) or head and neck (n = 0), i.e.,
cancers where radiotherapy is an important part of treatment. It is
well known that tumours derived from different tissues vary in
radiosensitivities; with haematological malignancies being sensi-
tive, and glioblastoma and melanomas the most radioresistant
[17]. Studies show that basal gene expression levels correlate
strongly with tissue of origin, particularly between haematological
and solid tumours [10]. As such, considerable variation and noise
is present in the NCI-60 ‘basal’ gene expression data, potentially
hampering the identification of genes associated with SF2. The
transcription factor P63 is a marker of squamous cell origin and
regulates many genes associated with epidermoid/squamous cell
fate. Loss of p63 is associated with the up-regulation of genes
associated with a more mesenchymal/migratory cell fate [18].
It was hypothesised that deriving a radiosensitivity signature
using a more homogeneous group of cell lines would be a better
approach. We obtained 16 cervical carcinoma cell lines, a tumour
type where radiotherapy is important but that is not represented in
the NCI-60 panel. The cells were characterised in tightly
controlled basal conditions; parameters measured included SF2,
protein expression by reverse-phase protein array (ZeptoMARK)
and gene expression by Affymetrix Exon 1.0ST array. We
attempted to identify genes that were differentially expressed
between high and low SF2 cell lines in a single homogeneous
tumour type. We had access to a second independent radiobio-
logically-relevant head and neck squamous cell carcinoma
(HNSCC) cell line cohort (n = 11) to validate our findings and
those derived from the publically available NCI-60 data.
Materials and Methods
Cell Lines
Fourteen commercially available cervical carcinoma cell lines
were obtained from the American Type Culture Collection
(ATCC) or the Japanese Collection of Research Bioresources
(JCRB). Two other cell lines (778 and 808) were derived in house
[19]. All cervix cell lines were cultured in identical conditions:
4.5 g/l glucose DMEM plus Glutamax (Life Technologies,
Paisley, UK), supplemented with 10% foetal calf serum (FCS)
(Lot: A04305-0160, PAA Laboratories (Yeovil, UK)) and kept in a
humidified incubator. Eleven head and neck cell lines were
cultured as described in Table S1. All cell lines underwent STR
authentication and were mycoplasma free.
Clonogenic Assays
The method is described elsewhere [20]. Briefly, exponentially
growing cells were trypsinised and irradiated with 0–10 Gy at
room temperature using an X-ray unit at a dose-rate of 1.37 Gy/
min. Following plating and 2–3 weeks growth, the colonies formed
were stained with crystal violet and those with .50 cells scored.
Each experiment involved a minimum of three but usually six
technical replicates and experiments were repeated two (n = 4) or
Figure 1. Radiobiological characterisation of cervix carcinoma cell lines. A) Radiation survival curves showing surviving fraction (log10) (y-
axis) following irradiation with 2, 4, 6, 8 and 10 Gy for 14 cervix cancer cell lines. Data points are the mean and standard error of 2–3 independent
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three (n = 21) times. Data shown are the mean of the biological
replicates.
HPV Genotyping
The HPV genotyping of these cervical carcinoma cell lines was
described previously [21]. For head and neck carcinoma cell lines
qRT-PCR for E2, E6 and E7 for HPV16 and HPV18 was
performed as described previously [22].
MTT Assay
Doubling time was estimated for each cell line using the
CellTiter 96 Aqueous Non-radioactive cell proliferation assay
(Promega, Madison, WI, USA) as per manufacturer’s ‘overnight’
protocol. A standard 7-day growth curve was performed in 96-well
plates. Colorimetric readings were taken at 570 nm and
compared, by exponential regression to a standard curve of
known cell density. An average of three independent replicates at
different densities was used to calculate the mean doubling time.
RNA Extraction
Cells were washed in PBS and snap-frozen in liquid nitrogen.
RNA was extracted and DNase treated using the Qiagen RNeasy
Kit (Qiagen, UK), as per manufacturer’s instructions. RNA
integrity (RIN) and quantification were measured using a
Bioanalyser (Agilent Technologies Ltd, Santa Clara, CA, USA).
260/230 and 260/280 ratios were assessed using a Nanodrop
1000 Spectrophotometer (Thermo Scientific, Wilmington, DE,
USA).
Western Blotting
The p63 protein status of the cervix carcinoma cell lines was
described previously [21]. Using the same methods Western
blotting was performed on the head and neck cell lines, using the
following antibodies: p63 mouse monoclonal (BC4A4) (Abcam,
Cambridge, UK) and anti-b-Actin mouse monoclonal (Clone AC-
15) (Sigma-Aldrich, Dorset, UK).
ZeptoMARK Reverse-phase Protein Arrays
Exponentially growing cells were washed with PBS, lysed in
75 ml of CLB1 lysis buffer (Zeptosens: a Division of Bayer
(Schweiz) AG, Switzerland), scraped into microfuge tubes,
vortexed and incubated at room temperature for 30 minutes.
Samples were centrifuged at 15,000 rpm at room temperature,
supernatants collected and concentrations determined by Bradford
assay. The spotting procedure has been described before [23].
Briefly, cervix carcinoma protein lysates were standardised to
2 mg/ml, from which four concentrations (0.20, 0.15, 0.10 and
0.05 mg/ml) were spotted, in duplicate onto a ZeptoMARK
hydrophobic chip (Zeptosens). Each cell line was independently
grown and harvested on two occasions; consequently two
biological replicates were spotted onto the array. Chips were
blocked with CeLyA buffer (Zeptosens), before incubation with
primary antibodies for 22 hours at 20uC. Twenty-four antibodies
(Zeptosens) were selected based on their role in cancer or therapy
resistance [24]. After incubation excess primary antibody was
removed and a fluorescently-labelled species-specific antibody
hybridised for 2.5 hours at 20uC. After washing, arrays were read
on a ZeptoREADER (lex/lem = 635/670 nm). The resulting
relative fluorescent intensity (RFI) was calculated from a standard
curve constructed from the four concentrations (in duplicate). This
is a quantitative protein measurement. Values displayed are the
mean of two biological replicates (i.e. 4 standard curves).
Exon Array Hybridisation
100 ng RNA was amplified using NuGen WT-Ovation FFPE
v2 kit (NuGen Technologies, San Carlos, CA, USA). The WT-
Ovation Exon Module V1.0 was used to generate ST-cDNA and
4 mg was hybridised to Human Exon 1.0 ST arrays (Affymetrix,
Santa Clara, CA). Further details and raw data (CEL files) are
Table 1. Summary characteristics of the cervix cell lines.
Cell line* Tumour histotype* SF2 HPV Genotype
$
p63{ (Western) TP63{ (array)
Boku SCC 0.4160.01 16 – 4.24
C33a Unknown 0.2560.01 – – 4.81
CaSki SCC 0.4760.02 16 + 8.67
HCS2 SCC N/A 18 + 8.86
HCSC1 Small cell carcinoma 0.3260.00 18 – 3.93
HeLa Adenocarcinoma 0.4160.04 18 – 4.54
HT3 Unknown 0.3560.12 – + 8.02
Me180 SCC 0.3560.01 68 + 10.33
MS751 SCC 0.4760.01 – + 8.51
SiHa SCC 0.7560.06 16 – 4.93
SKGI SCC 0.2760.09 18 + 7.2
SKGII SCC 0.3160.02 18 – 5.65
SKGIIIa Unknown 0.3760.03 16 + 8.6
SW756 SCC 0.4260.01 18 – 4.56
778 Unknown N/A 18 – 5.19
808 SCC 0.3360.02 18 + 8.28
*Provenance information from ATCC, JCRB or [17].
$
HPV genotype from [20].
{p63 expression from Western analysis and Exon derived array expression values from [19].
doi:10.1371/journal.pone.0086329.t001
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Figure 2. Transcriptional characterisation of the cervix cancer cell lines. A) Unsupervised hierarchical clustering of the top 1000 genes
ranked by coefficient of variation (from Exon array data). Heatmap colouring is by log2 expression value. Rows represent genes and columns are cell
lines. x-axis dendrogram (clusters) indicates the similarity of the cell lines and y-axis dendrogram the similarity of genes. Cluster 1 represents two
samples with the lowest TP63 values (p63 negative). Cluster 2 shows the grouping of the other p632 cell lines including the adenocarcinoma HeLa.
Radiosensitivity Signatures
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available at http://bioinformatics.picr.man.ac.uk/vice (or GEO:
GSE39066 (part of super series GSE39067). Raw data for
HNSCC cell lines are available at GEO: GSE51370.
Exon Array Data Analysis
Microarray data were normalised using RMA [25]. The R/
BioConductor package annmap and the annmap database [26]
were used to remove non-exonic and multi-targeting probesets.
Array performance was measured as the percentage of probesets
flagged as ‘‘present’’ with a conservative cut-off (%Detection
Above BackGround [%DABG] P,0.01) and only those probesets
flagged ‘‘present’’ in at least three samples were retained. This
filtering reduced the number of probesets considered from
1,411,399 to 353,981 exonic probesets, of which 243,301 passed
DABG filtering. Gene level summaries were calculated by taking
the median signal of filtered probesets that mapped to unique gene
symbols. When summarised this resulted in 31,345 genes
considered. Unsupervised hierarchical clustering was performed
on the 1000 most variant genes (ranked on coefficient of variation)
to show the separation of samples based on the most variable genes
in the data, while minimising computational requirements.
Signature Generation: A gene signature was determined to be
the set of genes or probesets that were significantly differentially
expressed between two groups of cell lines according to either
LIMMA or Rank Product Analysis. The cut-off for significance
was a false discovery corrected p value of 0.01. Packages: R: 3.0.2,
Annmap: v1.2.1 using human database build 66, LIMMA:
3.17.26, RankProd: 2.32.0, Pheatmap: 0.7.7.
Validation Cohorts, Array Mapping and Data Analysis
Head and neck cell line Affymetrix U133A Plus2 array data
were RMA normalised using the affy package in R. Affymetrix
control probesets (‘AFFX’ annotated) were removed. For variance
analysis, _x_, _a_ and _s_ annotated probesets were also removed.
NCI-60 - Affymetrix Plus2 cel files were downloaded from
CellMiner (http://discover.nci.nih.gov/cellminer/) and RMA
normalised as before. After normalisation, replicate arrays for
each cell line were averaged. For comparison to the gene-level
summarised exon array data, Plus2 probesets were mapped to
gene symbols using annmap.
Radiosensitivity Signature Mapping
All signatures were applied to the gene-level summaries of the
cervix data using gene symbol mapping. For application of
signatures to the HNSCC and NCI-60 Affymetrix Plus 2 datasets,
the following protocols were used:
1. Probeset IDs for the Eschrich et al [13] ten hub genes were
taken from Table 3 from the group’s first paper [13]. NCI-60
test set cell lines were taken from Table 4 from the group’s
second paper [12]. Twelve cell lines were listed but there was
no corresponding Plus2 array for the breast cell line MDN.
2. The top four ranking genes from Torres-Roca et al [14] (RPIA,
RBBP4, RGS19, ZNF208) were mapped to Affymetrix Plus2
probesets using annmap. The corresponding expression data for
the probesets were extracted and plotted on a linear scale (anti-
log).
3. Gene symbols for the Amundson et al gene signature were
taken from the second table of the original article [10]. One
gene could not be mapped (Unigene ID Hs.494347) as there
was no corresponding gene symbol in the table. The remaining
21 gene symbols were mapped to Plus2 probesets using annmap.
Multi-mapping probesets were removed.
4. The Tewari et al signature was taken from the second table of
the original article [8]. Forty-nine of the 60 probesets with a
unique gene symbol were extracted and mapped to Plus2
probesets using annmap. Multi-mapping probesets were
removed.
Unsupervised analyses (clustering, PCA) of gene expression
data, signature analysis and differential expression analysis
(LIMMA [27], RankProd) were carried out using R. The threshold
for differential expression using Rank Product Analysis (RankProd)
was a Percent False Positive (PFP) rate of ,0.01.
Graphing and Statistics
Results show the mean of biological replicates and precision
measurements are the standard error of mean unless otherwise
stated. R values indicate Pearson’s product moment coefficient.
Boxplots were generated in GraphPad Prism (v6.0): box-whisker
parameters: horizontal bar indicates median expression, the box
indicates interquartile range; whiskers represent the range. For
visualisation of radiation survival curves a linear quadratic
equation was fitted in R, with radiobiological parameters derived
from DRFIT [28]. The R package LIMMA, was used to calculate
differential expression values for protein profiling data. Where
appropriate, p-values are Benjamini and Hochberg false-discovery
rate (FDR) corrected [29]. Principal component analysis (PCA)
reduces multi-dimensional data (i.e. thousands of genes) into data-
points in 2-D space. The closer two data-points (samples) the more
similar the samples. PC1 (x-axis) accounts for the majority of
variance in an experiment, PC2 (y-axis) accounts for the
component representing the second highest variance.
Results
Cervical Carcinoma Cell Lines have a Range of
Radiosensitivities
Table 1 summarises the cervical carcinoma cell lines. Two cell
lines did not form colonies and SF2 values for the remaining 14
lines ranged from 0.25 to 0.75 (Figure 1). SF2 values for six of the
cell lines were published by another group [30], and the ranking
was identical in both studies. In the 14 cell lines, there was no
correlation of SF2 with plating efficiency (R2 = 0.005, p= 0.82),
doubling time (R2,0.0001, p= 0.99) or the RNA expression of
TP63, a marker of squamous cell differentiation (p= 0.90).
Molecular Characterisation of Seemingly Homogeneous
Cervical Carcinoma Cell Lines Shows Significant Disparity
p63 expression (protein and mRNA) was measured because it
discriminates between squamous (p63+) and non-squamous
Cluster 3 groups p63+ cell lines, with the exception of SKG1, which is classified with p63 negative cells. B) Principal component analysis of the 16
cervix cancer cell lines based on SCC (n = 1062), AC (n = 155) and small cell carcinoma (n = 77) gene expression. The x-axis shows principal component
1 (PC1) accounting for 15.5% of the variance. PC2 displayed on the y-axis accounts for 13.7% of the variance in the histology signature gene
expression. Colouring represents p63 protein expression. C) Graph showing the average expression (log2) of the SCC, AC and small cell carcinoma
signature. y-axis is the Exon array derived median gene level expression, for each of three signatures. X-axis shows the cell line. Cell lines are ranked
based on TP63 expression.
doi:10.1371/journal.pone.0086329.g002
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(p632) histological types of cervix cancer [21]. Following
transcriptional profiling, unsupervised clustering of the most
variant 1,000 genes (ranked by coefficient of variation) separated
the lines into three clusters (Figure 2A) with cluster 1 (C33a and
HCSC1) being outliers. The other 14 cell lines partitioned as
p632 and p63+ clusters with the exception of SKG1 which had
the lowest TP63 transcript level of the p63 positive lines. HCS2
and 778, which did not form colonies in our conditions, did not
cluster together suggesting no common transcriptional expression
associated with ability to form colonies. These results suggest that
the major basal transcriptional differences between the cell lines
relate to p63 expression. Interestingly, while HeLa cells were the
only adenocarcinoma (AC) according to provenance information,
several cervix cell lines had similar global transcriptional profiles.
HCSC1 is ‘small cell carcinoma’ derived, consequently we
explored whether the clustering of C33a and HCSC1 was due
to a shared histological origin. Principal component analysis (PCA)
using the combined gene expression from two gene signatures,
trained on (i) AC and SCC [21] and (ii) small cell carcinoma [31],
showed that HCSC1 and C33a had very similar histological gene
expression (Figure 2B). Figure 2C shows that C33a and HCSC1
had low levels of SCC genes and higher than average levels of
small cell carcinoma genes. It is interesting to note that the AC
gene expression was low in all cell lines, including HeLa,
suggesting that this signature, derived in primary tumour material
may have limited applicability in cell lines. These data suggest that
C33a is histologically a small cell carcinoma derived cell line and
highlights the transcriptional differences associated with histolog-
ical type found in a relatively homogeneous single tissue of origin
cohort.
Protein Profiling of ‘Cancer Associated Genes’ shows Key
Pathway Differences between Cell Lines, but not
between High and Low SF2 Groups
A panel of 24 proteins were selected from a catalogue of pre-
validated antibodies of proteins implicated in cancer, or resistance
to therapy [24]. Few DNA damage response antibodies were
available and so selection was limited to well-validated proteins
associated with cancer, such as p53, Rb, EGFR etc. As p63 is
essential for the proliferative potential of stem cells in stratified
epithelia [32], we postulated that p63+ cells would express higher
levels of the epithelial marker protein E-cadherin, compared with
p632 cells and this was confirmed by the protein array
(p=,0.0001) (Figure 3A). We also compared the mRNA
expression level of E-cadherin (Exon-array derived) with the
protein abundance measured by the array (relative fluorescence
intensity [RFI]; Figure 3B). There was a strong correlation
(R = 0.95, p,0.001) demonstrating that protein levels reflect
transcript levels for E-cadherin. We also detected high levels of
p53 protein in C33a cells compared with all other cell lines
(Figure 3C), due to a known mutation in the TP53 gene [33]
resulting in protein stabilisation. These data gave us high
confidence in the protein profiling data. Unsupervised clustering
of the protein data showed no relationships with known
characteristics (Figure S1). Ranking the cell lines by SF2 showed
no clear visual structure to the data (Figure 3C). The 14 cell lines
were split into high and low radiosensitivity groups using the
median SF2 value, as previously used with clinical specimens [3,4].
Four proteins were differentially expressed (p,0.05) between the
two groups: mTOR, PTEN, IkB alpha, and NFkB, but none were
significant after false discovery rate (FDR) correction (Figure 3D,
Table S2). mTOR was borderline significant (FDR p = 0.09) and
there was a trend for a moderate correlation between mTOR and
SF2 (R = 0.48, p= 0.08, Figure 3D). These data reveal that while
there were considerable differences between the cells in terms of
protein expression and pathway activation, none of the proteins/
pathways were robustly associated with SF2 in this cell line cohort.
Head and Neck Cancer Cell Lines Show Similarities in
Global Gene Expression
Table 2 summarises the 11 HNSCC cell lines, which were all
HPV negative (Figure S2). Although reported to be squamous cell
carcinoma, three lacked p63 protein expression by Western blot
(Figure S3), and had low transcript levels detected by microarray.
The SF2 range (0.3–0.8) was similar to that for the cervix lines
(Figure 4A), but the HNSCC cell lines were more radioresistant
compared with the cervix (p= 0.003). The median SF2, used to
partition the cell lines was 0.36 for cervix and 0.61 for HNSCC
cell lines. As with cervix cell lines, there was no difference in SF2
between cell lines expressing high versus low levels of TP63
(Figure 4B) and unsupervised hierarchical clustering partitioned
the HNSCC cell lines into three groups reflecting TP63 expression
(Figure 4C). The most outlying cluster had the lowest TP63
expression while the remaining two clusters divided the cell lines
with expression ,/.6.0 (log2) TP63. These data show that both
cervical carcinoma and HNSCC cell lines have similar radiosen-
sitivities and global transcriptional profiles, with the majority of
differences relating to the transcription factor p63. As such, the
HNSCC cohort is a tissue-type distinct from cervix, but should be
a good comparator for SF2 associated genes derived in cervical cell
lines and vice versa.
Genes Differentially Expressed between High and Low
SF2 Groups are Primarily Cell Type Specific and Cannot
Stratify the NCI-60 Cell Lines
Differences between the cell lines partitioned using median SF2
were explored using genome-wide expression profiling. No
differentially expressed transcripts were found by LIMMA follow-
ing multiple-testing correction. This was also the case for linear
models incorporating HPV and p63 expression as covariates, or in
a 3-way ANOVA. While genes were identified that were
differentially expressed (raw p,0.05), none passed false-discovery
Figure 3. ZeptoMARK protein profiling of the cervix cancer cell lines. A) Histogram displaying the ZeptoMARK protein-array derived
abundance for the 16 cervix cancer cell lines. The y-axis displays E-cadherin protein level (relative fluorescent intensity (RFI) for each of the cell lines
(x-axis). Cell lines are ranked based on TP63 expression. Grouping into p63 negative and p63 positive cell lines confirms the association of E-cadherin
with p63. The p value is T-test derived comparing the difference in E-cadherin expression between the p63 positive and negative groups, error bars
display standard deviation of two biological replicates. B) x–y scatterplot showing E-cadherin gene expression (Exon array) on the y-axis against E-
cadherin protein expression on the x-axis. Dashed line represents perfect correlation. Exon array data-points represent the average of multiple exonic
probesets (n = 19) from a single Exon expression array, where protein data are the mean of two biological replicates. C) Heatmap showing clustering
of proteins with similar expression (y-axis) in the ZeptoMARK protein profiling data. Cell lines ranked by SF2. Heatmap colouring is based on row Z-
score. D) xy-scatter plot showing the expression (y-axis) of the top 5 proteins from LIMMA against SF2 (x-axis). Table summarises the results of Limma
differential protein expression analysis between high and low SF2 groups and Pearson correlation of protein expression (RFI) against SF2. p values
denote those proteins with differential expression (* p,0.05 or ** p,0.01) between SF2 low and high groups according to LIMMA analysis. However
these fail to pass false discovery rate correction.
doi:10.1371/journal.pone.0086329.g003
Radiosensitivity Signatures
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correction. An alternative method, Rank Product Analysis, applied
to the cervix cell lines identified 96 differentially-expressed genes
(pfp,0.01) (Table S3). These genes separated the cervix samples
on the first principal component, accounting for 36% of the
variation (Figure 4D), but could not separate the HNSCC cell lines
based on SF2 (Figure S4A). A reciprocal analysis on the HNSCC
lines identified a similar number of probesets (n = 97, mapping to
42 unique gene symbols, pfp,0.01) differentially expressed
between high and low SF2 (Table S4). These genes performed
well in separating the HNSCC cell lines (Figure 4D), but failed to
separate the cervix lines (Figure S4B). This shows that the majority
of the genes identified are cohort/tumour type specific. Only four
(2.9%) of the 138 differentially expressed gene symbols were in
both gene lists: MGST1, IFITM2, TFPI and TGFB2. Of these only
two were congruent in being associated with radiosensitivity or
radioresistance in both cohorts (MGST1, TFPI). Expression of
these two genes did not separate the NCI-60 cell lines based on
SF2 (Figure 4D). Similar results were achieved taking the
convergence (n = 134) of the cervix and head and neck gene lists.
Identification and Independent Validation of a Signature
Associated with p63 Protein Expression
To test our signature generation approach, we applied the same
methods (i.e. Rank product, mapping Exon 1.0ST gene-level data
to U133 plus 2.0 array) to a more obvious biological phenotype:
p63 protein expression. Rank product analysis identified genes
differentially expressed between p63 positive and negative cell lines
in both cervix (n = 395) and HNSCC (n = 335) cell lines pfp,0.01
(Figure S5A&B). Of these genes 62 were differentially expressed in
both cell types and associated with p63 expression (Figure S5C).
These common genes represent genes previously associated with
squamous histology (e.g. KRT5, DSC3, CTA-55I10.1) [21].
Reassuringly, when this gene signature was applied to an
independent dataset it could discriminate between adenocarcino-
ma and squamous cell carcinoma of the lung (non-small cell lung
cancer) (Figure S6) [34]. There was little overlap between the p63
negative component of this signature and the adenocarcinoma
signature applied previously (Figure 2). Given HeLa is the only
adenocarcinoma cell line, this suggest that losing p63 expression is
not the same transcriptionally as being ‘adenocarcinoma’. In terms
of classification, it is predominantly the p63 positive component of
the signature that facilitates separation in both cell lines and
tumours. That said, as our methods could derive a signature
capable of independent validation, SF2 appears to be a difficult
phenotype to describe at the transcriptional level.
Figure 4. Characterisation of a head and neck squamous cell carcinoma (HNSCC) cell line cohort. A) Graph showing the mean SF2
(log10) (y-axis) for each of the 11 cervix cancer cell lines (x-axis). Error bars show the standard error of mean of 2–3 independent experiments. B)
Graph showing that there is no difference in TP63 expression between the SF2 high and low groups. Bar shows the median expression. C)
Unsupervised hierarchical clustering of the top 1000 genes ranked by coefficient of variation (from U133 array data). Heatmap colouring is by log2
expression value. Rows represent genes and columns are cell lines. x-axis dendrogram (clusters) indicates the similarity of the cell lines and y-axis
dendrogram the similarity of genes. Cluster 1 represents two samples with the lowest TP63 values (p63 negative). Cluster 2 shows the grouping of
the other p632 cell line, along with low TP63 expressing lines. Cluster 3 groups together all HNSCC lines with.6.0 (log2 expression) TP63 expression.
D) Diagram to represent the integrated SF2 analysis of the cervix and HNSCC cell lines. Rank product analysis (FDR ,0.05) identified 96 genes in the
cervix cohort differentially expressed between SF2 low and high cell lines. An identical analysis in the HNSCC cell lines identifies 97 probesets (42
genes) differentially expressed between SF2 low and high cell lines. PCA of the cervix genes shows that they are capable of separating the cell lines
by SF2. PCA of the HNSCC genes is equally capable of separating the samples based on SF2. The Venn diagram shows that only 4/138 genes are
common between the two cohorts and of these only 2/138 are ‘‘congruent’’ and associated with the same directionality (high SF2/low SF2 in both
HNSCC and cervix). PCA shows probeset expression of these two ‘‘common’’ and ‘‘congruent’’ genes (MGST1 and TFPI) in the NCI-60 dataset. The NCI-
60 upper PCA shows data-points coloured for median SF2 and lower PCA coloured for 0.2, used previously to partition radiosensitive and
radioresistant cell lines in this cohort.
doi:10.1371/journal.pone.0086329.g004
Table 2. Summary characteristics of the head and neck cancer cell lines.
Cell Line* Tumour sub-site* Tumour Histotype* SF2 HPV
$
p63{ (Western) TP63{ (array)
PE/CA PJ41 Oral squamous epithelium SCC 0.3360.01 – + 6.01
RPMI2650 Nasal septum SCC 0.4160.03 – – 4.47
PE/CA PJ34 Oral cavity SCC 0.4560.00 – + 6.6
Detroit 562 Pharynx SCC 0.4860.01 – + 5.62
CAL27 Tongue SCC 0.5260.01 – + 6.65
SW579 Thyroid SCC 0.6160.01 – – 4.46
OE21 Oesophagus SCC 0.6260.01 – + 6.48
PE/CA PJ15 Tongue epithelium SCC 0.6360.01 – + 5.69
FaDu Pharynx SCC 0.6760.01 – + 5.79
PE/CA PJ49 Tongue SCC 0.6860.02 – + 6.02
KYSE 30 Oesophagus SCC 0.8060.02 – – 4.97
*Provenance information was derived from ATCC including tissue origin and tumour histological type.
$
Table also includes the results of HPV genotyping (by HPV qRT-PCR),
{p63 expression from Western analysis and U133 plus 2.0 array derived TP63 expression values.
doi:10.1371/journal.pone.0086329.t002
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Figure 5. Assessment of established radiosensitivity gene signatures. A) PCA of the Tewari radiosensitivity gene signature. The original
signature consists of 49 genes, with mapping to the NCI-60 (60 Plus2 probesets) HNSCC (60 Plus2 probesets) and cervix cell line (48/49 genes)
datasets. The x-axis shows PC1, accounting for the largest amount of variation in the experiment and the y-axis shows the second principal
component (PC2). Colouring based on median SF2, blue data-points are radiosensitive cell lines (below the median SF2) with red data-points being
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Combined Analysis of Cervix and Head and Neck Cell
Lines Increases Statistical Power, but Fails to Give Rise to
a Robust Gene Signature Associated with SF2
Given our suspicion that there are only small transcriptional
differences associated with the SF2 phenotype, we calculated the
sample size required to detect transcriptional difference reflecting
SF2 from the cervix cell line data. Using gene CTC-359D24.3
which had the largest standardised difference between group
means of 2.48 (log2) combined with the smallest within group
standard deviation (1.54) provides an optimistic estimate of
required sample size for microarray classifiers [35]. This suggests
that 27 samples (13 SF2 low and 14 SF2 high) would be required
given the current spread of the data. The cohorts were combined
to improve statistical power (n = 25). The two cohorts were split
independently based on median SF2, as splitting on SF2 alone
would create a bias between the cervix and HNSCC samples
(Figure S7A). Samples below the median, whether cervix or head
and neck were defined as radiosensitive and above the median
were classified as radioresistant (Figure S7B). Twenty-two genes
were differentially expressed between the SF2 high and low
cohorts. These genes competently separated the cervix and
HNSCC cell lines, with only one misclassification (Figure S7A),
but did not separate the NCI-60 samples, whether separated on
the median or 0.2 (Figure S8) [10]. This suggests that the data are
potentially over-fitted and cannot generalise to the NCI-60
dataset. Interestingly 3/22 genes (KRT5, CSTA, FGFBP1) were
identified as being associated with p63 previously and suggest an
imbalance between histologies within the two SF2 groups.
Repeating the analyses using the overall median for the combined
cervix and HNSCC cell line cohort or the lowest quartile as a cut-
off did not improve the discriminatory power in the three cell line
cohorts. Similarly, pooling the cervix, HNSCC and NCI-60
cohorts did not work.
Published Radiosensitivity Gene Signatures have a
Varying Ability to Classify Cell Lines based on SF2
We also investigated published radiosensitivity gene signatures.
Given that principal component analysis (PCA) gives an unsuper-
vised/unbiased view of the major variation between different
samples we used this method to assess how well a gene signature
could separate samples based on SF2. First, we considered the
Tewari signature derived by assessing cell viability in in vitro
irradiated cervix tumour samples [8]. A 54 transcript signature
mapped to 49 unique gene symbols partly separated the cervix
(Figure 5A) but did not separate the HNSCC or NCI-60 cell lines
into SF2 groupings (Figure 5A).
The Torres-Roca signature was trained on a historical
microarray platform and when applied to the authors NCI-60
test subset [12] on a current array version (U133 plus 2.0) with
standard normalisation (RMA), did not predict SF2 in the NCI-60
test subset (Figure 5B), the cervix lines or the HNSCC cells
(Figure 5C). There was no statistically significant difference
between the calculated radiosensitivity index (RSI) and the SF2
groupings in either the cervix (p = 0.74) or HNSCC (p = 0.32) cell
lines (Figure S9) and no grouping by PCA when considering the
gene expression values for the ten ‘‘hub’’ genes (Figure S10). In a
subset of four published and described genes [12] there was a
weak, but significant correlation between expression of RPIA
(R =20.3, p,0.01), RBBP4 (R =20.36, p,0.01), RGS19
(R =20.4, p,0.01) and SF2, in the NCI-60 (training) data. These
genes however showed no association with SF2 in the cervix or
HNSCC cohorts (Figure S11). Taken together our findings suggest
that this gene signature, while capable of prognostication in
clinical datasets [11] and successfully classifying cell lines based on
SF2 in 5/12 (41.7%) cases, was not sufficiently robust to predict
SF2 on the same cell lines on a different microarray platform or in
independent cell line cohorts.
The last signature (Amundson) assessed was also derived using
the NCI-60 panel and the basal expression of genes associated
with SF2 [10]. Twenty-one genes partitioned the samples based on
an SF2 threshold of 0.2. This 21-gene signature separated the
NCI-60 cell lines according to SF2 along the first principal
component (Figure 5D). These genes also partly separated the
HNSCC cell lines using the second principal component. Similarly
the cervix cell lines showed grouping based on SF2, using the first
two principal components. These groupings are not ideal and
could be optimised further, but this demonstrates for the first time
that a gene signature trained on basal SF2 can be successfully
applied to two independent cell line cohorts. This suggests that
some genes associated with SF2 may generalise across cell-types,
rather than being cohort/cell type specific.
Discussion
Cell line-derived gene signatures have been successfully
translated to clinical biomarkers that are both prognostic and
predictive [36] and are particularly relevant in situations where
measurements in primary tumours are difficult, as with radiosen-
sitivity. Radiotherapy plays an important part in the management
of cervix cancer and HNSCC and measurements of radiosensi-
tivity have been shown to correlate with clinical radioresponse
[3,4]. The use of these tissue types is, however, currently under-
represented when training signatures on radiosensitivity [10,12].
As expected [30] the cervix cell line SF2 values varied but were
independent of proliferation and plating efficiency. We also
showed no association between SF2 and the expression of key
cancer associated proteins. However, mTOR was .20-fold higher
in radioresistant compared with radiosensitive cells and was
moderately correlated with SF2 (R = 0.48, p= 0.08). High
expression of mTOR protein was associated with a poor prognosis
in cervical cancer treated with radiotherapy [37]. Therefore,
mTOR may have a role in intrinsic radiosensitivity and clinical
radioresponse and should be investigated further.
A rationale of this study was that radiosensitivity signatures
might be improved if derived from homogeneous rather than
the radioresistant lines (above the median SF2). B) Implementation of the Eschrich radiosensitivity model [12]. Applied to a training set of 16 samples
from the NCI-60 [13]. xy-scatterplot with the x-axis showing reported SF2 values, generated with these cell lines on a earlier array type (U95) against
values generated by implementing the model in the current U133 plus 2.0 dataset (y-axis). Line indicates perfect correlation. C) Applied to the HNSCC
and cervix cancer cell line cohorts. The y-axis indicates the predicted SF2 determined from the radiosensitivity model. The x-axis shows the empirically
derived SF2 values. D) Principal component analysis of the Amundson radiosensitivity gene signature [10]. The original signature consists of 22 genes
(33 Plus2 probesets), with mapping to the NCI-60 (33 Plus2 probesets), HNSCC (33 Plus2 probesets) and cervix cell line (21/22 genes) datasets. The x-
axis shows PC1, accounting for the largest amount of variation in the experiment and the y-axis shows the second principal component (PC2). In the
NCI-60 data colouring is based a threshold of 0.2 (previously defined [21] where the HNSCC and cervix cell line datasets are coloured by median SF2.
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heterogeneous cell line cohorts involving multiple tissues of origin
and culture conditions. Despite the greater homogeneity of our
cohort, there were key differences between the cell lines.
Transcriptome analysis showed that C33a, commonly used as a
model for HPV negative cervix cancer [38], is likely to be derived
from small cell carcinoma and therefore may not be a good model,
given that most cervix cancers are squamous cell in origin [39].
The epithelial marker p63 that can be lost in culture by squamous
cells [18] was the most significant source of transcriptional
variation between cervix cell lines. We also show that p63 has
no association with SF2 in these cell lines. This result was also seen
in HNSCC lines, showing that SF2 in two independent cohorts of
cell lines is not associated with epithelial character.
HNSCC cell lines were similar to cervix cancer cell lines in their
SF2 range, basal gene expression and partitioning based on p63
status. However, radiosensitivity signatures did not transfer
between the tumour types. Only two genes (MGST1 and TFPI)
were differentially expressed between low and high SF2 groups in
both tumour types. There are a number of potential reasons for
this finding. First, cell lines from different origins may have
different mechanisms and consequential gene expression to deal
with radiation-induced damage. This is supported by different
tissues and their derivative cell lines having varying radiocurability
and radiosensitivity [17]. However, cervix and head and neck
cancer have broadly similar radiosensitivities and radiocurabilities.
Second, the simple dichotomisation strategy applied (i.e. median
partitioning of the cell lines) might not be the best approach,
however previous work in clinical samples showed that median
SF2 informed clinical radioresponse [3,4], and repeating the
analyses using a lower cut-off did not work. However, with a larger
cohort, perhaps including the extremes of SF2, a different
partitioning strategy might be more successful. Third, technical
variation in measuring SF2 might be a problem, particularly with
borderline samples. Fourth, differences in radiosensitivity (SF2)
occur at a post-transcriptional level and protein-profiling methods
may be more fruitful in deriving a radiosensitivity signature,
although these rely on the availability and selection of appropriate
antibodies [40]. Although there is interest in the protein expression
of DNA damage response, the literature is conflicting with high
expression associated with both good [41,42] and poor [40]
outcomes following radiotherapy. Another technical issue that
might account for the lack of transferability of the signatures is the
use of different platforms to measure gene expression. For example
the methods for filtering applied to the Exon 1.0ST arrays used to
generate the cervix signature cannot be applied to the U133 plus
2.0 arrays. However we show that this technical issue can be
overcome in the generation of a p63 signature, using the same
platforms (Figures S5 & S6).
Validation in an independent cohort is required to avoid over-
training of gene signatures but has been rarely applied for
radiosensitivity signatures. We tested three published signatures
trained on either SF2 or viability 48 h following 3 Gy irradiation.
The most developed signature trained on SF2 in the NCI-60 panel
did not validate. However, the normalisation (MAS 5.0) and array
type (HU6800) used in the original derivation and testing of the
signature were different and this may account for the lack of
reproducibility. This signature had been shown to be prognostic
for radioresponse (locoregional control) and predictive of benefit
from adjuvant radiotherapy in breast cancer patients [11].
Nevertheless, using the raw expression values alone or PCA
transformation showed no separation of the three datasets;
showing the signature is not sufficiently robust to transfer to other
cell line datasets.
A signature derived in cervix tumours based on viability 48 h
following 3 Gy irradiation [8] partly stratified the cervix lines, but
did not separate the HNSCC or NCI-60 lines. This observation is
consistent with our original hypothesis that radiosensitivity
signatures might be more robust if trained on more homogeneous
(and radiobiologically relevant) cell line cohorts. However, the
NCI-60 trained Amundson signature separated the cervix and
head and neck lines into high and low SF2 groups, albeit
imperfectly. This finding does not support our original hypothesis
but does suggest that further development of radiosensitivity
signatures is worthwhile. The research area will benefit from
expanding the number of cell line cohorts which have been well
characterised and for which gene expression data are available. It
is hoped that making our data publically available will aid further
developments of radiosensitivity signatures.
In summary, our attempt to identify common transcripts
associated with low and high SF2 measurements was not fruitful
in a homogeneous single tumour type cell line cohort. We applied
a relatively naı¨ve approach to identify the genes associated with
SF2. While it is likely that more advanced modelling of the data
will result in a better understanding of the data and potentially
reveal interesting candidate transcripts, this is beyond the scope of
this paper. What is clear from these analyses is that intrinsic
radiosensitivity, as measured by SF2, is a relatively subtle
phenotype. The datasets generated in this study should benefit
future work aimed at deriving a robust radiosensitivity signature.
Our work suggests that a common transcriptional signature can
reflect the radiosensitivity of tumours of heterogeneous origins,
although much larger cohorts are required to overcome
background noise.
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